论文信息 - Imbruvica (Ibrutinib): First Drug Approved for the Treatment of Patients with Waldenström's Macroglobulinemia.

Imbruvica (Ibrutinib): First Drug Approved for the Treatment of Patients with Waldenström's Macroglobulinemia.

Waldenstrom's macroglobulinemia (WM), also known as lymphoplasmacytic lymphoma, is an indolent subtype of B-cell non-Hodgkin lymphoma.1,2 WM is characterized by malignant B-cells that overproduce the abnormal monoclonal protein known as immunoglobulin (Ig) M or macroglobulin.2

Lisa A. Raedler

[1] R. Advani,et al. Ibrutinib in previously treated Waldenström's macroglobulinemia. , 2015, The New England journal of medicine.

[2] S. Rajkumar,et al. Waldenstrom macroglobulinemia: prognosis and management , 2015, Blood Cancer Journal.

[3] S. Treon,et al. The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis. , 2014, Blood.

[4] Yamei Chen,et al. Ibrutinib and novel BTK inhibitors in clinical development , 2013, Journal of Hematology & Oncology.

[5] N. Gray,et al. A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia. , 2013, Blood.

[6] N. Harris,et al. MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. , 2012, The New England journal of medicine.